ArticleClinical and experimental medicine2026
Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Ameliorates Testicular injury to improve spermatogenic disorder through PRDX1/TRAF6/TGFβ signaling pathway.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Infertility is a significant global health challenge, with male factors contributing to approximately 50% of cases. Here, this experiment investigated the effects of Umbilical Cord Mesenchymal Stem Cells (UCMSCs)-Derived Exosomes Ameliorates Testicular injury and its molecular mechanisms. In a mouse model of testicular injury, treatment with UCMSC-Exos improved spermatogenic dysfunction. We found that these exosomes carried and released PRDX1 mRNA. PRDX1 expression was downregulated in the injured testis, primarily within testicular epithelial cells. Knockdown of PRDX1 (sh-PRDX1) exacerbated spermatogenic disorder, whereas PRDX1 overexpression attenuated oxidative stress in vitro. PRDX1 reduced oxidative stress and inflammation in mice model of Testicular injury. PRDX1 reduced Epithelial fibrosis in Testicular injury model. PRDX1 reduced mitochondrial induced ferroptosis in Testicular injury model. The inhibition of PRDX1 promoted mitochondrial induced ferroptosis in Testicular injury model. PRDX1 suppressed TRAF6/TGFβ Signaling Pathway in mice model of Testicular injury. PRDX1 protein interlinked TRAF6 protein to promote TRAF6 ubiquitination in vitro model of Testicular injury. TRAF6 inhibitor reduced the effects of si-PRDX1 on ferroptosis and Epithelial fibrosis in Testicular injury model through the inhibition of oxidative stress and inflammation. Our findings demonstrate that UCMSC-derived exosomes ameliorate testicular injury and improve spermatogenic disorder. The mechanism involves the exosomal delivery of PRDX1, which subsequently interacts with TRAF6 to promote its ubiquitination, thereby inhibiting the TRAF6/TGFβ signaling pathway. This inhibition attenuates oxidative stress, inflammation, mitochondrial dysfunction-induced ferroptosis, and epithelial fibrosis, ultimately promoting testicular repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.